Community-acquired pneumonia primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Community-acquired pneumonia}} | {{Community-acquired pneumonia}} | ||
==Vaccines== | |||
{| style="border: 2px solid #696969;" align="center" | |||
|+ <SMALL>'' Vaccine prevention of community-acquired pneumonia.''<ref name="Harper-2005">{{Cite journal | last1 = Harper | first1 = SA. | last2 = Fukuda | first2 = K. | last3 = Uyeki | first3 = TM. | last4 = Cox | first4 = NJ. | last5 = Bridges | first5 = CB. | title = Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). | journal = MMWR Recomm Rep | volume = 54 | issue = RR-8 | pages = 1-40 | month = Jul | year = 2005 | doi = | PMID = 16086456 }}</ref></SMALL> | |||
| style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px"| '''Factor''' || style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px" | '''Pneumococcal polysaccharide vaccine''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''Route of administration''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Intramuscular injection''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''Type of vaccine''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸'''''Bacterial component (polysaccharide capsule)''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''Recommended groups''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸'''''All persons ≥ 65 years of age'''''<br>''''''High-risk persons 2–64 years of age''''''<br>''''''Current smokers'''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''Specific high-risk indications for vaccination''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Chronic cardiovascular, pulmonary, renal, or liver disease'''''<br>▸'''''Diabetes mellitus'''''<br>▸'''''Cerebrospinal fluid leaks ''''' <br>▸''''' Alcoholism ''''' <br>▸''''' Asplenia''''' <br>▸''''' Immunocompromising conditions / medications '''''<br>▸'''''Native Americans and Alaska natives '''''<br>▸'''''Long-term care facility residents''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''Revaccination schedule''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''One-time revaccination after 5 years for <br> ▸ (1) adults 65 years of age, if the first dose is received before age 65 years<br> ▸ (2) persons with asplenia <br>▸ (3) immunocompromised persons''''' | |||
|- | |||
|} | |||
Adapted from the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention.<ref name="Harper-2005">{{Cite journal | last1 = Harper | first1 = SA. | last2 = Fukuda | first2 = K. | last3 = Uyeki | first3 = TM. | last4 = Cox | first4 = NJ. | last5 = Bridges | first5 = CB. | title = Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). | journal = MMWR Recomm Rep | volume = 54 | issue = RR-8 | pages = 1-40 | month = Jul | year = 2005 | doi = | PMID = 16086456 }}</ref> | |||
==References== | ==References== | ||
Revision as of 21:01, 29 January 2014
|
Community-Acquired Pneumonia Microchapters |
|
Differentiating Community-acquired pneumonia from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Community-acquired pneumonia primary prevention On the Web |
|
American Roentgen Ray Society Images of Community-acquired pneumonia primary prevention |
|
Directions to Hospitals Treating Community-acquired pneumonia |
|
Risk calculators and risk factors for Community-acquired pneumonia primary prevention |
Vaccines
| Factor | Pneumococcal polysaccharide vaccine |
| ▸ Route of administration | ▸ Intramuscular injection |
| ▸ Type of vaccine | ▸Bacterial component (polysaccharide capsule) |
| ▸ Recommended groups | ▸All persons ≥ 65 years of age 'High-risk persons 2–64 years of age' 'Current smokers' |
| ▸ Specific high-risk indications for vaccination | ▸ Chronic cardiovascular, pulmonary, renal, or liver disease ▸Diabetes mellitus ▸Cerebrospinal fluid leaks ▸ Alcoholism ▸ Asplenia ▸ Immunocompromising conditions / medications ▸Native Americans and Alaska natives ▸Long-term care facility residents |
| ▸ Revaccination schedule | ▸ One-time revaccination after 5 years for ▸ (1) adults 65 years of age, if the first dose is received before age 65 years ▸ (2) persons with asplenia ▸ (3) immunocompromised persons |
Adapted from the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention.[1]